Pharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Pharma-Skan is a Danish CMO serving large corporations in the pharmaceutical and life sciences industries. With 45 years of consistent performance, the company specializes in the production, filling and packaging of liquid and sterile pharmaceuticals and oral liquids, as well as handling raw materials for both human and veterinary applications.
Skan-Medic, also based in Denmark, manufactures a range of OTC creams, lotions, ointments and other pharmacy-related products, including the patented Marselisborg Cream skin lotion, sold to pharmacies in Denmark.
The product portfolio includes both private label products and recurring contract work for large international pharmaceutical companies, such as the patented potassium chloride oral solution used to treat potassium deficiency, surface disinfectant ethanol for industrial cleaning and boar semen extenders. Operations are carried out in dedicated rooms for each stage of the process — sterile manufacturing, galenic formulation, packaging and quality control — backed by an experienced team with deep industry knowledge.
Brygge Partners is a Danish family office focused on long-term, mid-market acquisitions in the Nordic region, taking a hands-on approach to nurture and develop its portfolio companies.
Oaklins’ team in Denmark acted as the strategic and financial advisor to the owners of Pharma-Skan and Skan-Medic in this transaction.
Susanne Rasmussen
Co-owner, Pharma-Skan & Skan-Medic
Contáctese con el equipo de la transacción
Transacciones relacionadas
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Aprenda másEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Aprenda másOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Aprenda más